| 1. |
- Cho, Chaeyoon, et al.
(författare)
-
Observation-based estimates of the mass absorption cross-section of black and brown carbon and their contribution to aerosol light absorption in East Asia
- 2019
-
Ingår i: Atmospheric Environment. - : Elsevier BV. - 1352-2310 .- 1873-2844. ; 212, s. 65-74
-
Tidskriftsartikel (refereegranskat)abstract
- In this study, we estimated the contribution of black carbon (BC) and brown carbon (BrC) to aerosol light absorption from surface in-situ and aerosol robotic network (AERONET) columnar observations. The mass absorption cross-section (MAC) of BC (MAC(BC)) was estimated to be 6.4 +/- 1.5 m(2) g(-1) at 565 mn from in-situ aerosol measurements at Gosan Climate Observatory (GCO), Korea, in January 2014, which was lower than those observed in polluted urban areas. A BrC MAC of 0.62 +/- 0.06 m(2) g(-1) (565 mn) in our estimate is approximately ten times lower than MACK at 565 nm. The contribution of BC and BrC to the carbonaceous aerosol absorption coefficient at 565 nm from the in-situ measurements was estimated at 88.1 +/- 7.4% and 11.9 +/- 7.4%, respectively at GCO. Similarly, the contribution of BC and BrC to the absorption aerosol optical depth (AAOD) for carbonaceous aerosol (CA), constrained by AERONET observations at 14 sites over East Asia by using different spectral dependences of the absorption (i.e., absorption Angstrom exponent) of BC and BrC, was 84.9 +/- 2.8% and 15.1 +/- 2.8% at 565 nm, respectively. The contribution of BC to CA AAOD was greater in urban sites than in the background areas, whereas the contribution of BrC to CA AAOD was higher in background sites. The overall contribution of BC to CA AAOD decreased by 73%-87% at 365 nm, and increased to 93%-97% at 860 nm. The contribution of BrC to CA AAOD decreased significantly with increasing wavelength from approximately 17% at 365 nm to 4% at 860 nm.
|
|
| 2. |
- Hart, Robert G., et al.
(författare)
-
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status : The NAVIGATE ESUS Trial
- 2019
-
Ingår i: Journal of Stroke and Cerebrovascular Diseases. - : Elsevier BV. - 1052-3057. ; 28:8, s. 2273-2279
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Embolic stroke of undetermined source (ESUS) identifies patients with cryptogenic ischemic stroke presumed due to embolism from several unidentified sources. Among patients with recent ESUS, we sought to determine independent predictors of recurrent ischemic stroke during treatment with aspirin or rivaroxaban and to assess the relative effects of these treatments according to risk. Methods: Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4.6% per year). Baseline features were correlated with recurrent stroke by multivariate analysis. Results: The 7 independent predictors of recurrent stroke were stroke or transient ischemic attack (TIA) prior to the qualifying stroke (hazard ratio [HR] 2.03 95% confidence internal [CI] 1.58-2.60), current tobacco user (HR 1.62, 95% CI 1.24-2.12), age (HR 1.02 per year increase, 95%CI 1.01-1.03), diabetes (HR 1.28, 95% CI 1.01-1.64), multiple acute infarcts on neuroimaging (HR 1.49, 95% CI 1.09-2.02), aspirin use prior to qualifying stroke (HR 1.34, 95% CI 1.02-1.70), and time from qualifying stroke to randomization (HR .98, 95% CI .97-.99). The rate of recurrent stroke rate was 2.6% per year for participants without any of these risk factors, and increased by an average of 45% for each independent predictor (P < .001). There were no significant interactions between treatment effects and independent stroke predictors or stroke risk status. Conclusions: In this large cohort of ESUS patients, several features including prior stroke or TIA, advanced age, current tobacco user, multiple acute infarcts on neuroimaging, and diabetes independently identified those with an increased risk of ischemic stroke recurrence. The relative effects of rivaroxaban and aspirin were similar across the spectrum of independent stroke predictors and recurrent stroke risk status.
|
|
